By U.S. FDA — The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherap
Read the original at U.S. FDA ↗
Auto-published by the finit.news Events monitor from U.S. FDA; summarized by AI and may contain errors — verify against the primary source. November 5, 2026.